The purpose of this study is to evaluate efficacy and safety of CKD-351
Multi center, Randomized, Open-label, Active controlled, Phase 2 trial, Proof Of Concept Study to evaluate the efficacy and safety of CKD-351 in primary open angle glaucoma or ocular hypertension patients
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Latanoprost (25ug/ml), Dorzolamide (20mg/ml), twice a day
Latanoprost(50ug/ml) , once a day Dorzolmamide(20mg/ml), threetimes a day
Seoul National University Hospital
Seoul, South Korea
RECRUITINGChange in mean intraocular pressure for efficacy measurement
Change in mean intraocular pressure at 4 weeks compared to baseline
Time frame: Baseline, 4 weeks
Change in mean intraocular pressure for efficacy measurement
Change in mean intraocular pressure at 2 weeks compared to baseline
Time frame: Baseline, 2 weeks
Changes in intraocular pressure for efficacy measurement
Intraocular pressure by each measurement time
Time frame: Baseline, 2 weeks, 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.